AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set of quality standards (QS) to help improve the quality of healthcare provided to adult patients ...

The results of the incentives created by this tax structure were quite apparent ... As Senator Wyden and his team have highlighted, AbbVie systematically transfers nearly all the profits on ...

The move likely won’t have direct impact on most enterprise users, but indirect impact — which could be just as bad — is a definite possibility. Editor’s note: On Jan. 3, 2025, WordPress ...

Abbvie, Nanomedicine Innovation Center. Christian Macedonia does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article ...